Your browser doesn't support javascript.
loading
Effects of 1-year treatment with canagliflozin on body composition and total body water in patients with type 2 diabetes.
Matsuba, Ikuro; Takihata, Masahiro; Takai, Masahiko; Maeda, Hajime; Kubota, Akira; Iemitsu, Kotaro; Umezawa, Shinichi; Obana, Mitsuo; Kaneshiro, Mizuki; Kawata, Takehiro; Takuma, Tetsuo; Takeda, Hiroshi; Machimura, Hideo; Mokubo, Atsuko; Motomiya, Tetsuya; Asakura, Taro; Kikuchi, Taisuke; Matsuzawa, Yoko; Ito, Shogo; Miyakawa, Masaaki; Terauchi, Yasuo; Kanamori, Akira.
Afiliação
  • Matsuba I; The Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
  • Takihata M; The Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
  • Takai M; The Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
  • Maeda H; The Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
  • Kubota A; The Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
  • Iemitsu K; The Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
  • Umezawa S; The Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
  • Obana M; The Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
  • Kaneshiro M; The Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
  • Kawata T; The Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
  • Takuma T; The Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
  • Takeda H; The Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
  • Machimura H; The Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
  • Mokubo A; The Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
  • Motomiya T; The Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
  • Asakura T; The Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
  • Kikuchi T; The Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
  • Matsuzawa Y; The Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
  • Ito S; The Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
  • Miyakawa M; The Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
  • Terauchi Y; Department of Endocrinology and Metabolism, Yokohama City University, Yokohama, Japan.
  • Kanamori A; The Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama, Japan.
Diabetes Obes Metab ; 23(12): 2614-2622, 2021 12.
Article em En | MEDLINE | ID: mdl-34338409
ABSTRACT

AIM:

To characterize the long-term changes in body composition associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors. MATERIALS AND

METHODS:

In this multicentre, single-arm, open-label study, 107 patients with type 2 diabetes were treated with canagliflozin 100 mg, as add-on therapy, for 12 months. Body composition was measured with a body composition analyser (T-SCAN PLUS) using the impedance method to prospectively analyse changes in body components, including percentage of body fat, body fat mass, total body water, muscle mass and mineral mass. Estimated plasma volume (PV) was calculated using the Kaplan formula.

RESULTS:

Body weight showed a significant decrease from 1 month to 12 months of treatment with canagliflozin, with a higher rate of decrease in body fat in body composition. A significant decrease in mineral mass was also observed, but its rate was low. Following treatment with canagliflozin, changes in total body water did not affect intracellular water, and a significant decrease in extracellular water, including plasma components, was observed early and was sustained up to 12 months. Protein mass, a component of muscle mass, was not affected, with only a slight decrease in water volume observed.

CONCLUSIONS:

Canagliflozin decreased extracellular fluid and PV in addition to decreasing fat in the body via calorie loss resulting from urinary glucose excretion. This study suggested that SGLT2 inhibitors might reduce body weight by regulating fat mass or water distribution in the body and might have cardiac and renal protective effects by resetting the homeostasis of fluid balance.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Inibidores do Transportador 2 de Sódio-Glicose Idioma: En Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Inibidores do Transportador 2 de Sódio-Glicose Idioma: En Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão